Articles
In the May issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium on the association between prophylactic gabapentin, weight loss, and narcotic dependency in patients with oropharyngeal cancer undergoing radiation therapy. Read More ›
- FDA Approves First and Only Blood-Based Colorectal Cancer Screening Test
- Imbruvica Now FDA Approved for First-Line Treatment of Patients with CLL
- Gazyva Approved for the Treatment of Relapsed or Refractory Follicular Lymphoma
- Ibrance Receives an Expanded Indication in Breast Cancer
- Kyprolis Receives New Indication for Relapsed or Refractory Multiple Myeloma
- FDA Grants Priority Review for Venetoclax as a Potential New Treatment for CLL
This therapy is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD) who develop renal or pulmonary dysfunction after undergoing hematopoietic SCT. Read More ›
By Wayne Kuznar
San Antonio, TX—A pilot study found that 70% of patient participants believed that text messages served as a reminder to take their endocrine therapy and wanted to continue receiving them. Read More ›
Atlanta, GA—Pharmacists involved in this program followed discharged patients and helped to decrease the number of readmissions in this population. Read More ›
And other news from the 12th HOPA Annual Conference
The ability to analyze multiple genes at the same time has led to the estimate that 20% to 25% of women with ovarian cancer have an inherited mutation in a cancer‑predisposing gene. Although this association has been noted for a while, until recently there was not enough data available to determine the lifetime ovarian cancer risk for women with a mutation in some of these genes. Read More ›
Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non–small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. NSCLC comprises several disease histologies, including adenocarcinoma, squamous-cell carcinoma, nonsquamous carcinoma, large-cell anaplastic carcinoma, and adenosquamous carcinoma. Read More ›
The year 2015 marked a noteworthy 12-month period for oncology drugs approved by the US Food and Drug Administration (FDA). The Center for Drug Evaluation and Research, which reviews the approval of antibodies and small molecules, approved a total of 45 new drugs in 2015; 15 of which are indicated for the treatment of cancer. Read More ›
Colony-stimulating factors (CSFs) are endogenous glycoproteins that regulate the production and the functioning of infection-protective granulocytes and macrophages. Overall, 2 types of recombinant CSF drugs—granulocyte CSF (filgrastim, pegfilgrastim) and granulocyte-macrophage CSF (sargramostim)—have been prescribed for more than 20 years to stimulate neutrophils and macrophages, primarily in patients with cancer who are undergoing treatment with cytotoxic chemotherapy. Read More ›
A critical part of care planning for patients with cancer is the prevention and management of chemotherapy-induced nausea and vomiting (CINV), one of the most feared side effects of chemotherapy. Overall, 70% to 80% of patients with cancer experience CINV in the absence of appropriate CINV prophylaxis. Read More ›